Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martínez E; DOLAM study group. Rojas J, et al. Lancet HIV. 2021 Aug;8(8):e463-e473. doi: 10.1016/S2352-3018(21)00100-4. Lancet HIV. 2021. PMID: 34358497 Clinical Trial.
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial.
de Lazzari E, Di Gregorio S, Rojas J, Curran A, Domingo P, Negredo E, Tiraboschi J, Gonzalez-Cordon A, Torres B, Sempere A, Inciarte A, Gatell JM, Blanco JL, Martinez E; DOLAM study group. de Lazzari E, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2226-2233. doi: 10.1093/jac/dkaf192. J Antimicrob Chemother. 2025. PMID: 40556520 Clinical Trial.